Efaroxan

Efaroxan (RX 821037) is a benzofuranyl imidazoline compound developed at Reckitt and Colman Products Limited in the 1980s as a potent and selective alpha-2 adrenergic receptor antagonist with concurrent affinity for the imidazoline I1 receptor and functional blockade of ATP-sensitive potassium (KATP) channels on pancreatic beta cells. The compound is structurally related to idazoxan (the benzodioxan reference alpha-2 antagonist) but is distinguished by a dihydrobenzofuran ring system in place of the benzodioxan, by marked stereoselectivity in its dual pharmacology, and by a research literature that extends substantially beyond adrenergic receptor pharmacology into the domains of insulin secretion, neuroprotection, and cognitive facilitation. At the alpha-2 adrenoceptor, the (+)-enantiomer of efaroxan binds with low-nanomolar affinity (Ki approximately 26 nM at the human alpha-2A subtype, approximately 36 nM at alpha-2C, approximately 132 nM at alpha-2B) and 300- to 5000-fold selectivity over the (-)-enantiomer, while maintaining approximately 724-fold selectivity over alpha-1 adrenoceptors. The (-)-enantiomer, which is essentially devoid of alpha-2 antagonist activity, retains full KATP channel blocking capacity and stimulates insulin secretion from pancreatic beta cells through a mechanism that is glucose-dependent and involves both KATP channel closure and a KATP-independent pathway that sensitizes the exocytotic machinery to calcium. This stereoselective dissociation of adrenergic and metabolic activities, first characterized in the Reckitt and Colman patent literature and subsequently confirmed in isolated islet and in vivo glucose tolerance studies, is a pharmacologically distinctive feature that has positioned efaroxan as a tool compound for dissecting the relative contributions of alpha-2 antagonism and direct beta-cell effects to insulin secretagogue activity.

Preclinical pharmacology extends across multiple domains. In the central nervous system, (+)-efaroxan facilitates norepinephrine and acetylcholine release in cortical and hippocampal circuits, produces neuroprotection against quinolinic acid-induced excitotoxic lesions of the striatum at 0.63 mg/kg in the published literature in rats, ameliorates hippocampal damage and cognitive deficits following cerebral ischemia, and enhances dopaminergic circling behavior in 6-hydroxydopamine-lesioned rats through a stereoselective mechanism consistent with alpha-2 receptor blockade. At ultra-low doses (1.3 ng intrathecal), (+)-efaroxan stereoselectively inhibits the development of acute morphine tolerance and blocks opioid-induced hyperalgesia in spinal models, suggesting a role for alpha-2 adrenoceptor modulation in opioid tolerance mechanisms. In peripheral metabolic pharmacology, the antihyperglycaemic potency of racemic efaroxan in glucose-tolerant and diabetic mouse models is attributable predominantly to alpha-2A antagonism at the pancreatic beta cell, with the (+)-enantiomer improving oral glucose tolerance at 100-fold lower doses than the (-)-enantiomer, and the combination of efaroxan with the sulphonylurea glibenclamide producing synergistic insulinotropic effects that exceed those of either agent alone.

Clinical evidence is limited. A single prospective randomized, double-blind, placebo-controlled, crossover trial of efaroxan (2 mg in the published literature for 12 weeks) in 14 patients with progressive supranuclear palsy found no significant change on motor assessment criteria, and the authors concluded that alpha-2 receptor blockade did not represent a useful pharmacological strategy for that condition. The compound has not been advanced to registration for any indication and is not approved by any regulatory authority. It is supplied exclusively as a research-grade preparation by multiple chemical suppliers at greater than 98 percent purity. Investigators should confirm identity, purity, and enantiomeric composition on every lot and should consider the stereoselective pharmacology as a critical determinant of experimental interpretation, particularly in studies combining adrenergic and metabolic endpoints.